Primary Immune Thrombocytopenia (ITP) Clinical Trial
Official title:
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia (ITP)
This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in patients with primary ITP.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04812483 -
Immunomodulation With Eltrombopag in ITP
|
Phase 2 | |
| Active, not recruiting |
NCT05029635 -
Phase III Study on HMPL-523 for Treatment of ITP
|
Phase 3 | |
| Completed |
NCT06408324 -
Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe
|
||
| Recruiting |
NCT05338190 -
Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia
|
Phase 3 | |
| Completed |
NCT02042560 -
Study of Immune Thrombocytopenia Pathogenesis:
|
N/A | |
| Recruiting |
NCT05653349 -
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
|
Phase 3 | |
| Recruiting |
NCT05718856 -
TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
|
Phase 4 | |
| Recruiting |
NCT05885555 -
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
|
Phase 2 | |
| Recruiting |
NCT04518475 -
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
|
Phase 4 |